Medifocus (PK) Stock Price

0.00 (0.0%)


52 Week Range


Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
Ultimate Trader (Monthly)
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Medifocus Inc (PK) MDFZF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.002 16:30:13
Open Price Low Price High Price Close Price Prev Close
0.002 0.002
Bid Price Ask Price Spread News
0.0001 0.01 0.0099 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.002 USD

Medifocus (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 369.97k 184.98M 130.73M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
2.89k $ - 0.00% - -

more financials information »

Medifocus (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MDFZF Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.00240.00240.00130.0021,283,513-0.0004-16.67%
1 Month0.00310.00310.00130.0020085646,757-0.0011-35.48%
3 Months0.01170.01170.00130.0022386141,277-0.0097-82.91%
6 Months0.0020.016150.00130.002962775,0460.000.0%
1 Year0.00910.016150.00130.003559561,246-0.0071-78.02%
3 Years0.026670.0310.00110.00676981,794-0.02467-92.5%
5 Years0.0250.05140.00110.010566763,413-0.023-92.0%

Medifocus (PK) Description

Medifocus, Inc. (TSXV-MFS, OTC-MDFZF) is a leader in the use of focused microwave energy to treat cancer and other tumors. It owns two fully developed technology platforms with comprehensive US and international patent protection: (1) The Endo-thermotherapy Platform-a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The U.S. FDA approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH) was developed based on the Endo-thermotherapy and is currently generating revenue, and (2) The Adaptive Phased Array (APA) Microwave Focusing Platform-invented by MIT, licensed to Medifocus, directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company?s APA 1000 Breast Cancer Treatment System, developed from the APA technology platform has received approval from the U.S. FDA and Health Canada to conduct the pivotal Phase III clinical trials. The Company believes that these two technology platforms can provide the design basis for the development of multiple cancer treatment systems for surface, subsurface and deep seated localized and regional cancers.

Your Recent History
Medifocus ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.